Penicillin
Fleming's Mould, the Oxford Team, and Wartime Mass Production
- 20 chapters
- 37m
- Pharmacology
- Free · no sign-up
The audiobook covers penicillin units, types, and natural forms. It explains how 6-APA became the foundation for new antibiotics. Chapters detail penicillin G and V, their side effects, and how they enter bacteria. The book examines resistance mechanisms, structure determination, and total synthesis methods.
From Fleming's mold to wartime mass production, this account covers the entire development process. It includes deep-tank fermentation techniques that scaled up production dramatically. The book also addresses early antibiotic resistance issues that emerged during this period.
Anyone interested in pharmaceutical history will find this comprehensive guide worth their time.
Listen
-
Read this chapter
Alexander Fleming first used the term “penicillin” on 7 March 1929, when he identified the antibacterial properties of a mould called Penicillium rubens. In his paper published in the British Journal of Experimental Pathology, Fleming said he wanted to avoid repeating the long phrase “Mould broth filtrate,” so he would call it “penicillin” instead. The name comes from the scientific name of the mould itself, which Fleming described in his Nobel lecture in 1945.
People have often asked me why I chose the name “Penicillin.” I was simply following standard practice, creating a term that showed the substance came from a plant in the genus Penicillium. This approach was similar to how “Digitalin” had been named earlier, for a compound taken from the plant Digitalis.
In modern terms, penicillin describes any β-lactam antimicrobial containing a thiazolidine ring fused to the β-lactam core, whether natural or not. Like many natural compounds, the active substances found in Penicillium moulds occur as mixtures. Gentamicin offers another instance of a naturally occurring substance that lacks a defined set of active components. The main active constituents of Penicillium are detailed in the table below.
Penicillium produces several active compounds besides penicillin G, including penicillin O, penicillin U1, and penicillin U6. Some substances once thought to be penicillin-like were later identified as not actually having antibiotic properties; for example, penicillin A was found to lack activity and isn't chemically related to the antibiotics we know as penicillins. These distinctions help clarify what truly counts as a functional penicillin in nature.
The exact type of penicillin produced depends on which kind of Penicillium mould is used and what nutrients the mould is grown on. Fleming’s original Penicillium rubens strain mainly creates penicillin F, named after him. But penicillin F is unstable, hard to separate from other substances, and the mould makes only small amounts of it.
When corn steep liquor is used as the culture medium, the Peoria strain of Penicillium chrysogenum produces penicillin G as its main output. But if phenoxyethanol or phenoxyacetic acid are added to that same medium, the mould shifts its production and creates penicillin V instead.
6-Aminopenicillanic acid, or 6-APA, comes from penicillin G and holds the beta-lactam core while missing its side chains. Because of this, it's a key starting point for making other kinds of penicillin. From 6-APA, scientists create semi-synthetic versions grouped into three types: antistaphylococcal, broad-spectrum, and antipseudomonal. Even though they're modified, all these are still called penicillins because they come from penicillin G at the base.
-
Read this chapter
When we measure penicillin G, one unit equals 0.600 micrograms. So if you're looking at 2 million units—sometimes called 2 megaunits—then that’s exactly 1.2 grams of the drug. This standard became essential during wartime, when the need for mass production was urgent. The Oxford team took on the challenge of making sure there was enough of this powerful medicine to treat both soldiers and civilians. They worked hard to turn scientific knowledge into real-world help on a scale never attempted before.
The way penicillin was measured in units is mostly outdated now, except in the U.S. Back when penicillin was first made, it was a messy mix of compounds, so its strength changed from batch to batch. That made it impossible to give a dose like “1 gram” because what you got could vary wildly. So instead, each batch was tested and standardized using a known amount—like a vial labeled 5,000 Oxford units in the 1940s. But even that vial might hold between 15 and 20 milligrams of the actual drug. Later, a million international units became the standard, which could contain between 2.5 and 3 grams of natural penicillin. With the rise of purer forms like penicillin G, a white powder, there’s little need for unit-based dosing anymore—though units are still used in the U.S. for one specific form, benzathine benzylpenicillin.
The measurement of penicillin has changed three times since its discovery, with each new standard designed to match the last closely. This evolution happened as scientists worked to define how strong the antibiotic really was. The process involved contributions from Fleming, who first found the mold, and later teams at Oxford who helped improve its use. These efforts took place during wartime, when making large amounts of the drug became necessary for treating infections. Each step in defining the unit kept it close to earlier measurements, so that the effectiveness of penicillin could be trusted and repeated across different times and places.
In 1941, the Oxford unit was established as the standard for measuring penicillin, defined as the amount needed to inhibit a specific bacteria in 50 milliliters of meat extract. This original measure relied on a large batch of impure penicillin stored in Oxford. Later, Florey’s team refined the method into what became known as the cup assay. In this test, one unit per milliliter was determined when 339 microliters of solution created a 24-millimeter clear zone around a plate of solid agar, stopping the growth of the Oxford Staphylococcus.
In 1944, the International Standard for penicillin was established at The National Institute for Medical Research in Mill Hill, London, using an 8-gram batch of pure crystalline penicillin G sodium. From that, one unit was set at 0.6 micrograms. A second, more widely distributed standard was also created, known as the working standard, where each unit weighed 2.7 micrograms due to impurities. Around the same time, the cup assay method was improved, replacing a simple 24 mm zone measurement with a more accurate approach using reference curves to determine potency.
In 1953, a team reached a major milestone in penicillin standardization. They produced a single 30-gram batch of pure crystalline penicillin G sodium, stored at Mill Hill. This sample became known as the Second International Standard. From this, they defined one penicillin unit as exactly 0.5988 micrograms. This precise measurement helped ensure consistency in medical treatments across the world. The work was part of a larger effort to make penicillin production reliable and uniform during and after the war. The standardization process made it possible to measure doses accurately, no matter where treatment was given. It also marked a turning point in how antibiotics were regulated and distributed globally.
There’s an older unit used for penicillin V that doesn’t match the current standard. The reason is that the U.S. FDA made a mistake by thinking penicillin V had the same potency per mole as penicillin G. But penicillin V is actually less potent, and the present unit for penicillin V takes that difference into account.
In 1959, the first international unit of penicillin V was established. One unit was defined as 0.590 micrograms of a reference standard kept at Mill Hill in London. That standard became the measure for penicillin V across nations, though it's no longer used today. The reference material was held in a specific location, and the definition itself was precise down to the microgram. This unit represented a major step in standardizing antibiotics for global medical use. The system was later replaced, but that original definition marked an important moment in pharmaceutical history.
-
Read this chapter
Penicillins are defined by a specific molecular structure, including a 4-membered beta-lactam ring, a thiazolide ring, and an R side chain. The key difference between various types of penicillins lies in that R group, which varies from one type to another. This family of antibiotics includes many variants, each distinguished by the particular chemical makeup of its side chain. These structural details matter because they determine how the drug interacts with bacteria. The Oxford team worked on understanding these differences during wartime production efforts. Fleming’s mould was the original source, but it was the work of scientists at Oxford that helped unlock the potential for mass-producing different kinds of penicillin. The R substituent is what makes each version unique in its action and use.
The side chain attached to the 6-aminopenicillanic acid residue creates differences in how each type of penicillin works. These variations affect the range of bacteria they can fight, how stable the drug is, and whether it can resist being broken down by beta-lactamases. This structural detail explains why there are multiple forms of penicillin, each with its own set of properties and uses.
-
Read this chapter
Penicillin G, also known as benzylpenicillin, comes from a type of fungus called penicillium that exists in nature. The specific strain used today was made through genetic engineering to boost production efficiency. This improvement helped meet the high demand during wartime. None of the other natural penicillins—like Penicillin F, K, N, X, O, U1, or U6—are being used in treatments now.
-
Read this chapter
There are three major groups of semi-synthetic antibiotics built on the same foundation as penicillin. They start with a basic structure called 6-APA, which comes from penicillin G. Scientists then attach different side-chains to this core molecule to create new antibiotics. These include antistaphylococcal, broad-spectrum, and antipseudomonal types. Each group targets different kinds of bacteria, expanding the usefulness of the original discovery. The process allows for more varied and effective treatments, building on what was first found in nature.
-
Read this chapter
In the 1960s and 1970s, scientists worked hard to create new antibiotics that could fight Pseudomonas aeruginosa, a type of bacteria that resists many common antibiotics. This Gram-negative species proved especially tricky to treat. Two main types of antibiotics were developed for this purpose: carboxypenicillins and ureidopenicillins. All of these medications had to be given by injection because none could be taken orally.
-
Read this chapter
Penicillin G can't be taken by mouth because stomach acid breaks it down, so it has to be given through an injection into a muscle or directly into the vein. Even though doses can reach up to 2.4 grams—much higher than penicillin V—it needs to be administered frequently due to how quickly the kidneys flush it out of the blood. It's available in two forms made from an insoluble salt: procaine penicillin and benzathine benzylpenicillin. Because of its rapid elimination, maintaining a strong level in the bloodstream requires regular dosing.
Penicillin G was approved to treat a wide range of serious bacterial infections, including septicaemia, empyema, pneumonia, pericarditis, endocarditis, and meningitis caused by susceptible staphylococci and streptococci. It also treated anthrax, actinomycosis, cervicofacial disease, thoracic and abdominal conditions, clostridial infections, botulism, gas gangrene—often alongside surgery or debridement—and tetanus, used together with immune globulin. It helped in diphtheria cases, both as an aid to antitoxin treatment and to prevent carriers, and was effective against erysipelothrix endocarditis, fusospirochetosis affecting the oropharynx, lower respiratory tract, and genital area, as well as Listeria infections, Pasteurella infections including bacteraemia and meningitis, Haverhill fever, rat-bite fever, disseminated gonococcal infections, meningococcal meningitis and septicaemia, and syphilis.
-
Read this chapter
Penicillin V is taken orally because it withstands stomach acid better than other forms. Doses over 500 milligrams don’t work as well due to poor absorption. It treats the same bacterial infections as penicillin G and is the most commonly used version of penicillin. However, it's not suitable for serious conditions like endocarditis, which require high levels of penicillin in the blood.
-
Read this chapter
Penicillin can cause a range of side effects, some common and others less frequent. Diarrhoea, rash, nausea, and hypersensitivity are among the reactions that occur in at least one percent of users. Neurotoxicity and superinfections like candidiasis are also possible. Infrequent but serious effects include fever, vomiting, and pseudomembranous colitis, which happen in less than one percent of cases. Some people may develop serum sickness or a similar reaction weeks after starting treatment. This isn’t a true allergy—it’s a type III response—but repeated exposure can lead to anaphylaxis. Allergic reactions occur in about one to ten percent of patients, usually as a skin rash. IgE-mediated anaphylaxis is rare, affecting roughly point zero one percent of individuals.
When people receive injections of certain penicillin drugs like benzathine benzylpenicillin or procaine benzylpenicillin, they may experience pain and swelling at the injection site. This reaction is called livedoid dermatitis or Nicolau syndrome. It's a known side effect of these medications, especially the parenterally administered ones. The condition causes inflammation and discomfort where the drug was injected. While it’s not uncommon, it’s still a recognized issue that healthcare providers monitor closely during treatment.
-
Read this chapter
The penicillins all share a common core structure known as "penam," which has the molecular formula R-C9H11N2O4S, where R is the varying side chain that sets each penicillin apart. This core, called 6-APA, has a molar mass of 243 g/mol and is built from a dipeptide made of L-cysteine and D-valine. That combination creates the β-lactam and thiazolidinic rings. Some penicillins, like cloxacillin, reach nearly 450 g/mol in size, with cloxacillin specifically at 436 g/mol.
The essential feature of penicillin’s structure is a four-membered ring called the β-lactam ring, which is vital for its ability to fight bacteria. This ring is connected to another five-membered ring known as thiazolidine. Because these two rings are fused together, the β-lactam ring becomes more chemically reactive than similar rings that aren’t joined this way. That’s because the fusion distorts the amide bond in the ring, removing a usual kind of chemical stabilization. Attached to this main structure is an acyl side chain.
Following the discovery of penicillin, scientists worked to modify its structure in order to create new antibiotics. One key molecule, 6-APA, became the foundation for many chemical changes. By altering the acyl side chain, researchers developed variations like methicillin. This version included methoxy groups at positions 2' and 6' on the benzene ring of 6-APA, compared to penicillin G. These changes made methicillin resistant to β-lactamase, an enzyme that many bacteria use to break down penicillins. The result was a more effective antibiotic, showing how small chemical adjustments could lead to important medical advances.
-
Read this chapter
Penicillin works well against gram-positive bacteria because these organisms lack an outer membrane and are enclosed only by a thick cell wall. The penicillin molecules are small enough to move through the spaces between the glycoproteins in that wall. This is why gram-positive bacteria are especially vulnerable to penicillin, as first shown when penicillin was discovered in 1928.
Penicillin enters gram-negative bacteria differently than it does gram-positive ones. These bacteria have a thinner cell wall but an extra outer membrane made of lipopolysaccharide chains that blocks water-soluble molecules like penicillin, offering natural resistance. Still, penicillin can get in through porous channels called porins, which are embedded in the outer membrane and let in nutrients and some antibiotics. The rate depends on how big the penicillin molecule is—penicillin G moves slowly because it's large, while smaller versions like ampicillin and amoxicillin pass through faster. Vancomycin, being too big, can't get through at all, making it useless against gram-negative bacteria. The number and size of porins vary between bacterial species, so susceptibility to penicillin changes accordingly.
-
Read this chapter
Penicillin works by stopping bacteria from building their cell walls. It targets the final steps in making peptidoglycans, the structural parts of those walls. The drug blocks enzymes needed for cross-linking these peptidoglycans, using a specific part of its structure called the β-lactam ring. When the cross-links are reduced, the cell wall becomes weak. Water rushes into the cell because it can't keep up the right balance, and that leads to the cell bursting and dying.
Bacteria build and break down their cell walls as they grow and divide, using a process that involves peptidoglycan. In the final steps of this process, a molecule called UDP-MurNAc is formed, which includes two D-alanine amino acids. The enzyme DD-transpeptidase helps connect these molecules, creating cross-links that give the cell wall its strength. Penicillin mimics the structure of D-alanine and binds to this enzyme instead. By doing so, it stops the formation of cross-links, disrupting the cell wall. Without proper structure, the bacteria can't maintain their integrity and die quickly.
Penicillin works by targeting the cell wall of bacteria, specifically interfering with the balance between enzymes that build and break down peptidoglycan. While the enzymes that break down these cross-links keep working, the ones that form them stop, weakening the wall. This imbalance leads to cytolysis, where osmotic pressure causes the bacterium to burst and die. The buildup of peptidoglycan precursors also activates autolysins—enzymes that digest the cell wall even more. Because penicillins are small molecules, they can fully penetrate the bacterial cell wall, making them highly effective. This is different from larger antibiotics like vancomycin and teicoplanin, which cannot reach the same depth.
When gram-positive bacteria lose their cell walls, they become known as protoplasts. Gram-negative bacteria, on the other hand, don’t lose their cell walls entirely and are referred to as spheroplasts after being treated with penicillin. This distinction highlights how the antibiotic affects different types of bacteria in unique ways, depending on their cellular structure.
Penicillin works better when paired with aminoglycosides, a combination that boosts their ability to fight bacteria. Because penicillin stops the formation of peptidoglycan, which is part of the bacterial cell wall, it makes it easier for aminoglycosides to get inside the cell. Once inside, these aminoglycosides disrupt the bacteria’s protein-making process. This teamwork lowers the minimum bactericidal concentration needed to kill the bacteria, especially for strains that are susceptible to both drugs.
Penicillins, which belong to a group of antibiotics called β-lactams, stop bacteria from dividing—this includes not just common bacteria, but also cyanobacteria. They also interfere with the division of cyanelles, the photosynthetic parts inside glaucophytes, and chloroplasts found in bryophytes. However, these antibiotics don’t affect the plastids of more advanced vascular plants. This difference supports the idea that plastid division in land plants evolved through endosymbiosis.
Some bacteria fight back against penicillin by producing enzymes called β-lactamases that break down the antibiotic's structure. To combat this, doctors sometimes pair penicillin with clavulanic acid or tazobactam, which are β-lactamase inhibitors. These drugs shut down the enzyme permanently, letting the penicillin do its job. Another approach uses flucloxacillin, a modified version of penicillin with an acyl side chain that protects the beta-lactam ring from being destroyed by β-lactamase, giving it activity against resistant strains.
-
Read this chapter
Penicillin moves through the body in ways that affect how well it works. It doesn’t bind strongly to proteins in the blood, which means more of the drug stays active and available. When it comes to how much gets absorbed, penicillin G is less effective—only below 30% makes it into the system. Penicillin V does better, with between 60 and 70% being absorbed. These differences matter for how doctors decide which kind to use.
Penicillin doesn’t stay in your body very long—it has a short half-life and gets filtered out by the kidneys. That’s why it used to have to be given four times a day to keep levels up. Early guides even suggested giving injections every three hours, which was compared to trying to fill a bath with the plug out. These days, larger doses are easy and cheap to get, so that strict schedule isn’t needed anymore. Still, some experts suggest using continuous infusions instead.
-
Read this chapter
When Alexander Fleming first found penicillin in 1928, he noticed that some bacteria weren’t affected by it. Later, in 1940, Ernst Chain and Edward Abraham figured out how this happened. They discovered that bacteria like Escherichia coli make enzymes that break down penicillin, making it useless. They called this enzyme penicillinase. Today, penicillinase is known as a type of β-lactamase. These enzymes are found in many bacteria and are made when bacteria are exposed to antibiotics. Bacteria can become resistant through three main methods: limiting the antibiotic’s entry, reducing how well it binds to its target, or destroying it with β-lactamase. This leads to multi-drug resistance, where bacteria survive multiple antibiotics at once.
Resistance in bacteria can be complicated, especially when it comes to how penicillin enters the cell. In gram-positive bacteria like S. aureus, resistance often happens because the cell wall becomes thicker, made extra peptidoglycan that blocks the drug from getting in. But in gram-negative bacteria, the issue is usually with porins—tiny channels in the outer membrane. For example, Pseudomonas aeruginosa has fewer of these porins, while Enterobacter, E. coli, and Klebsiella pneumoniae have changed versions like non-specific porins such as OmpC and OmpF that simply can’t transport penicillin effectively.
Bacteria fight back against penicillin by altering the proteins needed to build their cell walls. In Streptococcus pneumoniae, changes in genes that make PBPs reduce how well the antibiotic binds. Six mutant PBPs exist in this bug, with PBP1a, PBP2b, PBP2x, and occasionally PBP2a causing that drop in binding. Staphylococcus aureus can turn on a hidden gene to make a different PBP called PBD2, which also binds poorly to penicillin. A strain of S. aureus known as MRSA developed resistance after methicillin appeared in 1959. Mutations in the mec system in MRSA create a variant protein named PBP2a—or PBP2'—that doesn’t bind well to penicillin and lacks the activity needed for peptidoglycan production. Helicobacter cinaedi has multiple gene mutations that produce PBP variants.
During experiments in 1940 testing penicillin’s purity and activity, scientists discovered that E. coli was resistant to the drug. The reason was later found to be an enzyme called penicillinase, the first β-lactamase known, produced by the bacteria and capable of breaking down penicillin. This mechanism of resistance became known as enzymatic destruction by β-lactamases and was described as “the greatest threat to the usage [of penicillins].” There are over 2,000 types of these enzymes, each with a unique amino acid sequence and specific target site, all able to hydrolyse β-lactam rings. They’re secreted in large quantities on the surface of gram-positive bacteria but less so in gram-negative ones, which means that in mixed infections, gram-positive bacteria can protect susceptible gram-negative cells.
Pseudomonas aeruginosa has some unusual ways of defending itself against antibiotics. One of these involves biofilms—layers of protective material that can form around the bacteria. These biofilms help the bacteria survive treatment. Another mechanism is the creation of persister cells, which are able to tolerate multiple drugs at once. These cells don’t die even when exposed to strong antibiotics. This makes infections caused by P. aeruginosa especially hard to treat.
-
Read this chapter
In the late 19th century, reports emerged of Penicillium mould killing bacteria, though no one understood the process behind it. A Scottish doctor named Alexander Fleming worked at St. Mary’s Hospital in London, which is now part of Imperial College. On 3 September 1928, he accidentally noticed that a fungal contaminant in a bacterial culture of Staphylococcus aureus seemed to destroy the bacteria. He did a second experiment on 28 September 1928 and confirmed his findings. Fleming published his work in 1929, calling the antibacterial substance he discovered penicillin.
C. J. La Touche determined the fungus was Penicillium rubrum, a classification that would later be adjusted by Charles Thom, who reclassified it as P. notatum and P. chrysogenum, only to have it corrected again as P. rubens. Fleming initially saw potential in penicillin as an antiseptic, noting its powerful effect and low toxicity when compared with other antiseptics of the era. He also recognized its usefulness in laboratory settings, particularly in isolating Bacillus influenzae, now identified as Haemophilus influenzae.
Fleming's work didn't gain support from other scientists, largely because penicillin was so hard to isolate that turning it into a usable drug seemed impossible. Some believe that if Fleming had better drawn others into his research, the development of penicillin might have happened years sooner.
The recognition of Alexander Fleming’s work includes a special tribute at the Alexander Fleming Laboratory Museum in London, where an International Historic Chemical Landmark was installed on 19 November 1999.
-
Read this chapter
On November 25th, 1930, Cecil George Paine, a pathologist working at the Royal Infirmary in Sheffield, used a fungal extract to treat an infant suffering from ophthalmia neonatorum, a severe gonococcal eye infection. This case marked a significant moment in early medical use of penicillin.
In 1940, Howard Florey, a scientist from Australia and his team at Oxford's Sir William Dunn School of Pathology including Ernst Chain and Norman Heatley, figured out how to make concentrated penicillin from fungus culture broth that killed bacteria both in lab tests and in living subjects. The following year, they treated a policeman named Albert Alexander who had a severe facial infection; he got better but ran out of penicillin and later died. Other patients were treated successfully after that. Then, in December 1942, burn victims from the Cocoanut Grove fire in Boston became the first patients to be saved using penicillin treatment.
In 1942, Fleming used penicillin to treat Harry Lambert, who had a deadly infection of the nervous system. By then, the Oxford team could only make tiny amounts, so Florey gave Fleming the one sample they had. Lambert improved within a day and was fully recovered in a week. Fleming reported the case in The Lancet in 1943. After this success, the British War Cabinet formed the Penicillin Committee on 5 April 1943 to begin planning how to make large quantities of the drug.
-
Read this chapter
As people began to understand how useful penicillin could be, the team at Oxford realized they couldn’t make enough of it in their lab. When their efforts to get support from the British government didn’t work, Florey and Heatley packed up their mould samples and headed to the United States in June 1941. They went to the Northern Regional Research Laboratory in Peoria, Illinois, which was part of the U.S. Department of Agriculture. That lab had the right equipment for making large amounts of the mould. Soon after, they started growing it on a massive scale and looked for even better strains.
On 14 March 1942, Anne Miller became the first patient treated with US-made penicillin from Merck & Co., using half of the total supply available at the time. By June 1942, just enough was produced for ten patients. In July 1943, the War Production Board planned how to distribute penicillin to Allied troops in Europe. Fermentation research using corn steep liquor from the NRRL allowed the U.S. to produce 2.3 million doses in time for the Normandy invasion in 1944. A mouldy cantaloupe in Peoria, Illinois was found to contain the best strain for production, increasing output sixfold over Fleming’s original mould. Jasper H. Kane of Pfizer suggested using a deep-tank fermentation method, and Margaret Hutchinson Rousseau developed a large-scale plant for this process. By June 1945, the war effort had led to over 646 billion units per year being produced.
G. Raymond Rettew advanced the American war effort by applying his expertise in mushroom cultivation to a process that used the Sharples Cream Separator, enabling large-scale penicillin production. By 1943, his lab was supplying most of the world’s penicillin. During the Second World War, this breakthrough significantly lowered death and amputation rates from infected wounds among Allied forces, saving an estimated 12–15% of lives. Still, shortages persisted due to the challenges of manufacturing large quantities and the drug's rapid removal by the kidneys, which required frequent dosing. Methods for mass-producing penicillin were later patented by Andrew Jackson Moyer in 1945. Florey chose not to patent penicillin after being advised by Sir Henry Dale that such an action would be unethical.
During the early days of penicillin, when the drug was so rare and valuable that doctors would collect patients’ urine to recover any leftover penicillin, researchers searched for ways to keep more of the medicine in the body. They hoped to find a molecule that could block penicillin’s excretion by competing with it for a specific transporter. The uricosuric agent probenecid worked well for this, as it competitively inhibited the removal of penicillin, boosting its effectiveness and duration. Although the development of mass-production techniques and semi-synthetic penicillins eventually solved supply problems, probenecid is still used today in cases where very high levels of penicillin are needed.
After the Second World War, Australia became the first country to make penicillin available for civilian use. In the United States, the drug was made available to the general public on 15 March 1945.
-
Read this chapter
In 1942, Edward Abraham put forward the first proposal for penicillin’s chemical structure. That suggestion was later confirmed in 1945, when Dorothy Crowfoot Hodgkin at Oxford used X-ray crystallography to verify it. She would go on to win the Nobel Prize in Chemistry in 1964 for this work and other structural studies she'd done.
John C. Sheehan, the chemist at MIT, finished the first chemical synthesis of penicillin in 1957. He had begun his research into penicillin synthesis back in 1948. During those studies, he created new methods for making peptides and developed new protecting groups—chemical tools that reduce the reactivity of certain parts of molecules. Although Sheehan’s original synthesis wasn’t suitable for producing penicillin on a large scale, one of the compounds he made along the way was 6-aminopenicillanic acid, or 6-APA. That compound turned out to be the core structure of penicillin.
In 1957, researchers at Beecham Research Laboratories in Surrey discovered 6-APA, a key component later published in 1959. This breakthrough allowed scientists to attach different chemical groups to the 6-APA nucleus found in penicillin, creating new and more effective forms of the antibiotic.
-
Read this chapter
The original penicillin had a limited range of infections it could treat, and when doctors tried to make it work better, they looked for ways to improve it. One key step was isolating 6-APA, which is the core structure of penicillin. With that discovery, scientists were able to create semisynthetic versions of the drug—derivatives that had better properties than the original benzylpenicillin. These new forms offered improved absorption, a broader spectrum of activity, greater stability, and better tolerance in patients.
The first major step forward came in 1961 with ampicillin, which broadened the range of bacteria it could fight compared to the original penicillins. Scientists kept working, and soon developed β-lactamase-resistant penicillins like flucloxacillin, dicloxacillin, and methicillin. These were especially useful against bacteria that produced the enzyme β-lactamase, but they eventually lost their effectiveness against MRSA, a strain of Staphylococcus aureus resistant to methicillin.
The story of penicillin didn’t stop with the original discovery. Scientists built on that work to create new versions, like carbenicillin, ticarcillin, and piperacillin, which were especially good at fighting certain types of bacteria. But the real power of penicillin came from a key part of its structure called the β-lactam ring. That same ring stayed at the center of other important antibiotics, including mecillinams, carbapenems, and most importantly, cephalosporins. These drugs kept that core feature because it made them so effective.
-
Read this chapter
Penicillin comes from a fungus called Penicillium rubens, which grows during a process known as fermentation. This fungus uses sugars as its food source, and in doing so, it creates penicillin as a byproduct. The creation of penicillin happens when the fungus is under stress, which stops its growth. There's a specific chemical pathway involved in making penicillin, and it includes a step where another substance, l-lysine, slows down an enzyme called homocitrate synthase. This slowdown is known as feedback inhibition.
To grow Penicillium cells for penicillin, scientists use a method known as fed-batch culture, where the cells experience continuous stress necessary to trigger production. The process is influenced by several factors: glucose, when used as a carbon source, suppresses the enzymes needed for penicillin synthesis, whereas lactose has no such effect. Alkaline pH levels can override this repression. Additionally, high phosphate levels, plenty of oxygen, and the presence of ammonium as a nitrogen source all inhibit production, while methionine, acting as a nitrogen and sulfur source, enhances it.
Scientists used biotechnology to create many new strains of Penicillium through directed evolution. This method involves causing mutations in the fungi using techniques like error-prone PCR, DNA shuffling, ITCHY, and strand-overlap PCR. These approaches allowed researchers to develop improved versions of the mould that produces penicillin. The work was part of a larger effort to make the antibiotic more effective and easier to produce on a large scale. By changing the genetic structure of the mould, scientists could enhance its ability to create penicillin. This process helped lay the groundwork for mass production during wartime. The techniques were not only scientific but also essential for meeting the urgent medical needs of the time. These advances in mould development were crucial to the success of penicillin as a life-saving drug.
Read
Free to download, keep and share. For general information only — not professional medical, legal or financial advice. Please consult a qualified professional.